Breakpoints (mg/L) of dalbavancin, oritavancin and vancomycin for Gram-positive organisms causing acute bacterial skin and skin structure infections (ABSSSI)
| Pathogen . | Druga . | FDA/CLSI M100 . | EUCAST . | |||
|---|---|---|---|---|---|---|
| S . | I . | R . | S ≤ . | R> . | ||
| Staphylococcus spp. | Dalbavancin | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin | ≤0.12 | b | b | |||
| Oritavancin, S. aureus | 0.125c | 0.125d | ||||
| Vancomycin, S. aureus | ≤2 | 4–8 | ≥16 | 2 | 2 | |
| Vancomycin, coagulase- negative | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Enterococcus spp. | Dalbavancine | ≤0.25 | b | b | IE | IE |
| Oritavancin | ≤0.12 | b | b | IE | IE | |
| Vancomycin | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Streptococcus: Groups A, B, C, and G | Dalbavancin | 0.125c | 0.125d | |||
| Oritavancin | 0.25c | 0.25d | ||||
| Vancomycin | 2 | 2 | ||||
| Streptococcus: β-haemolytic group | Dalbavancinf | ≤0.25 | b | b | ||
| Oritavancin | ≤0.25 | b | b | |||
| Vancomycin | ≤1 | b | b | |||
| Streptococcus: viridans group | Dalbavancin, S. anginosus group | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin, S. anginosus group | ≤0.25 | b | b | 0.25c | 0.25d | |
| Vancomycin | ≤1 | b | b | 2 | 2 | |
| Pathogen . | Druga . | FDA/CLSI M100 . | EUCAST . | |||
|---|---|---|---|---|---|---|
| S . | I . | R . | S ≤ . | R> . | ||
| Staphylococcus spp. | Dalbavancin | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin | ≤0.12 | b | b | |||
| Oritavancin, S. aureus | 0.125c | 0.125d | ||||
| Vancomycin, S. aureus | ≤2 | 4–8 | ≥16 | 2 | 2 | |
| Vancomycin, coagulase- negative | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Enterococcus spp. | Dalbavancine | ≤0.25 | b | b | IE | IE |
| Oritavancin | ≤0.12 | b | b | IE | IE | |
| Vancomycin | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Streptococcus: Groups A, B, C, and G | Dalbavancin | 0.125c | 0.125d | |||
| Oritavancin | 0.25c | 0.25d | ||||
| Vancomycin | 2 | 2 | ||||
| Streptococcus: β-haemolytic group | Dalbavancinf | ≤0.25 | b | b | ||
| Oritavancin | ≤0.25 | b | b | |||
| Vancomycin | ≤1 | b | b | |||
| Streptococcus: viridans group | Dalbavancin, S. anginosus group | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin, S. anginosus group | ≤0.25 | b | b | 0.25c | 0.25d | |
| Vancomycin | ≤1 | b | b | 2 | 2 | |
IE, there is insufficient evidence that the organism or group is a good target for therapy with the agent.
Lipoglycopeptide MICs are method dependent (broth microdilution in the presence of 0.002% polysorbate-80 is the reference method).
The absence of resistant clinical isolates precludes defining any results other than ‘Susceptible’.
Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.
Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
For reporting against vancomycin-susceptible E. faecalis only.
For reporting against S. pyogenes, S. agalactiae, and S. dysgalactiae.
Breakpoints (mg/L) of dalbavancin, oritavancin and vancomycin for Gram-positive organisms causing acute bacterial skin and skin structure infections (ABSSSI)
| Pathogen . | Druga . | FDA/CLSI M100 . | EUCAST . | |||
|---|---|---|---|---|---|---|
| S . | I . | R . | S ≤ . | R> . | ||
| Staphylococcus spp. | Dalbavancin | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin | ≤0.12 | b | b | |||
| Oritavancin, S. aureus | 0.125c | 0.125d | ||||
| Vancomycin, S. aureus | ≤2 | 4–8 | ≥16 | 2 | 2 | |
| Vancomycin, coagulase- negative | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Enterococcus spp. | Dalbavancine | ≤0.25 | b | b | IE | IE |
| Oritavancin | ≤0.12 | b | b | IE | IE | |
| Vancomycin | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Streptococcus: Groups A, B, C, and G | Dalbavancin | 0.125c | 0.125d | |||
| Oritavancin | 0.25c | 0.25d | ||||
| Vancomycin | 2 | 2 | ||||
| Streptococcus: β-haemolytic group | Dalbavancinf | ≤0.25 | b | b | ||
| Oritavancin | ≤0.25 | b | b | |||
| Vancomycin | ≤1 | b | b | |||
| Streptococcus: viridans group | Dalbavancin, S. anginosus group | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin, S. anginosus group | ≤0.25 | b | b | 0.25c | 0.25d | |
| Vancomycin | ≤1 | b | b | 2 | 2 | |
| Pathogen . | Druga . | FDA/CLSI M100 . | EUCAST . | |||
|---|---|---|---|---|---|---|
| S . | I . | R . | S ≤ . | R> . | ||
| Staphylococcus spp. | Dalbavancin | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin | ≤0.12 | b | b | |||
| Oritavancin, S. aureus | 0.125c | 0.125d | ||||
| Vancomycin, S. aureus | ≤2 | 4–8 | ≥16 | 2 | 2 | |
| Vancomycin, coagulase- negative | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Enterococcus spp. | Dalbavancine | ≤0.25 | b | b | IE | IE |
| Oritavancin | ≤0.12 | b | b | IE | IE | |
| Vancomycin | ≤4 | 8–16 | ≥32 | 4 | 4 | |
| Streptococcus: Groups A, B, C, and G | Dalbavancin | 0.125c | 0.125d | |||
| Oritavancin | 0.25c | 0.25d | ||||
| Vancomycin | 2 | 2 | ||||
| Streptococcus: β-haemolytic group | Dalbavancinf | ≤0.25 | b | b | ||
| Oritavancin | ≤0.25 | b | b | |||
| Vancomycin | ≤1 | b | b | |||
| Streptococcus: viridans group | Dalbavancin, S. anginosus group | ≤0.25 | b | b | 0.125c | 0.125d |
| Oritavancin, S. anginosus group | ≤0.25 | b | b | 0.25c | 0.25d | |
| Vancomycin | ≤1 | b | b | 2 | 2 | |
IE, there is insufficient evidence that the organism or group is a good target for therapy with the agent.
Lipoglycopeptide MICs are method dependent (broth microdilution in the presence of 0.002% polysorbate-80 is the reference method).
The absence of resistant clinical isolates precludes defining any results other than ‘Susceptible’.
Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.
Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
For reporting against vancomycin-susceptible E. faecalis only.
For reporting against S. pyogenes, S. agalactiae, and S. dysgalactiae.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
